Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

ZS Pharma

- PMLiVE

EMA sets aside £32m for temporary staff to help with Brexit move

As agency warns current tender system needs to be updated

- PMLiVE

EMA faces ‘permanent damage’ if forced to go to an unpopular city

Warns eight candidate cities wouldn't retain minimum staff numbers it needs

- PMLiVE

AZ buoyed by latest lung cancer data at ESMO

Data from separate Tagrisso and Imfinzi trials show superior PFS among patients

- PMLiVE

Dismay as NICE turns down first-line use of AZ’s Faslodex

Says evidence isn’t convincing for use in post-menopausal women

- PMLiVE

UK life sciences sector sets out its post-Brexit growth proposals

Review helmed by Sir John Bell outlines a wide-ranging strategy

AZ and Medimmune bolsters immuno-oncology leadership

Dr Jean-Charles Soria and Dr Geoffrey Kim join the company

- PMLiVE

Most of the EU would like to host the EMA

Nineteen member states will compete to host the agency when it leaves the UK

AstraZeneca AZ

After MYSTIC setback, FDA gives some comfort to AZ

Awards its PD-L1 inhibitor Imfinzi breakthrough status in locally-advanced NSCLC

AstraZeneca AZ

Shock for AZ as MYSTIC trial stumbles at first hurdle

Combination fails to improve progression-free survival for lung cancer patients

- PMLiVE

CHMP backs three immuno-oncology drugs for solid tumours

Roche, MSD and Merck/Pfizer are all on course for new European approvals later this year

- PMLiVE

Sanofi and Regeneron win CHMP nod for Dupixent

Atopic dermatitis treatment backed for European approval

AstraZeneca AZ

AZ on the slide again as CEO departure rumours bubble away

Soriot’s alleged departure makes investors nervous ahead of looming MYSTIC trial results

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links